| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communications |
From the Department of Pathology, Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Göteborg University, Göteborg, Sweden
Gastrointestinal stromal (pacemaker cell) tumors (GIST/GIPACTs) are frequently associated with activating KIT mutations, primarily of exon 11 and rarely of exons 9 and 13, as well as certain chromosome rearrangements. Reports regarding the frequency and prognostic significance of KIT mutations are conflicting and few cases have been completely sequenced. Furthermore, there are few detailed analyses of chromosome alterations in GIST/GIPACTs. In a detailed analysis of 14 GIST/GIPACTs from 12 patients, we found a wider spectrum of KIT mutations than previously reported, including 11 different in-frame mutations involving exons 11, 14, and 15. No mutations were detected in four malignant tumors. The shorter (GNNK-) KIT isoform was preferentially expressed. Cytogenetic and spectral karyotype analyses of 10 tumors revealed clonal abnormalities in eight tumors; the most common were terminal 1p deletions and losses of chromosomes 14 and/or 22. Neither KIT mutation status nor chromosome aberrations correlated with tumor phenotype or clinical behavior in our series. Collectively, these findings indicate that the role of KIT mutations and chromosomal rearrangements in the pathogenesis of GIST/GIPACTs are more complex than previously recognized.
Related articles in Am J Pathol:
This article has been cited by other articles:
 |
|
 |
|
  H. Bougherara, F. Subra, R. Crepin, P. Tauc, C. Auclair, and M.-A. Poul The Aberrant Localization of Oncogenic Kit Tyrosine Kinase Receptor Mutants Is Reversed on Specific Inhibitory Treatment Mol. Cancer Res., September 1, 2009; 7(9): 1525 - 1533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Kim, M.-H. Ryu, H. Lee, S. J. Sym, J.-L. Lee, H. M. Chang, Y. S. Park, K. H. Lee, W. K. Kang, D. B. Shin, et al. Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors Oncologist, May 1, 2009; 14(5): 540 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Tornillo and L M Terracciano An update on molecular genetics of gastrointestinal stromal tumours. J. Clin. Pathol., June 1, 2006; 59(6): 557 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gotlib, C. Berube, J. D. Growney, C.-C. Chen, T. I. George, C. Williams, T. Kajiguchi, J. Ruan, S. L. Lilleberg, J. A. Durocher, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation Blood, October 15, 2005; 106(8): 2865 - 2870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kimura, N. Jones, M. Kluppel, M. Hirashima, K. Tachibana, J. B. Cohn, J. L. Wrana, T. Pawson, and A. Bernstein Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages PNAS, April 20, 2004; 101(16): 6015 - 6020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Kaelin Jr. Gleevec: Prototype or Outlier? Sci. Signal., March 23, 2004; 2004(225): pe12 - pe12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gonzalez, E. J. Andreu, A. Panizo, S. Inoges, A. Fontalba, J. L. Fernandez-Luna, M. Gaboli, L. Sierrasesumaga, S. Martin-Algarra, J. Pardo, et al. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis Clin. Cancer Res., January 15, 2004; 10(2): 751 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Antonescu, G. Sommer, L. Sarran, S. J. Tschernyavsky, E. Riedel, J. M. Woodruff, M. Robson, R. Maki, M. F. Brennan, M. Ladanyi, et al. Association of KIT Exon 9 Mutations with Nongastric Primary Site and Aggressive Behavior: KIT Mutation Analysis and Clinical Correlates of 120 Gastrointestinal Stromal Tumors Clin. Cancer Res., August 1, 2003; 9(9): 3329 - 3337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rosai GIST: An Update International Journal of Surgical Pathology, July 1, 2003; 11(3): 177 - 186. [PDF]
|
|
|
|
|
|
R. Dagher, M. Cohen, G. Williams, M. Rothmann, J. Gobburu, G. Robbie, A. Rahman, G. Chen, A. Staten, D. Griebel, et al. Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors Clin. Cancer Res., October 1, 2002; 8(10): 3034 - 3038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid Oncologist, October 1, 2002; 7(5): 393 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Fletcher, C. D.M. Fletcher, B. P. Rubin, L. K. Ashman, C. L. Corless, M. C. Heinrich, J. Andersson, H. Sjogren, J. Meis-Kindblom, G. Stenman, et al. KIT Gene Mutations in Gastrointestinal Stromal Tumors : More Complex than Previously Recognized? Am. J. Pathol., August 1, 2002; 161(2): 737 - 739. [Full Text] [PDF]
|
|
|
|
|
|
J. Lasota, J. Kopczynski, M. Majidi, M. Miettinen, and M. Sarlomo-Rikala Apparent KIT Ser715 Deletion in GIST mRNA Is Not Detectable in Genomic DNA and Represents a Previously Known Splice Variant of KIT Transcript Am. J. Pathol., August 1, 2002; 161(2): 739 - 741. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
